Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular

Status Recruiting

Clinical Trial Summary

Radiofrequency ablation of ventricular tachycardias (VTs) is the gold standard treatment of refractory VTs in patients with ischaemic heart disease. In this setting, ablation is usually performed endocardially. However, even after a procedural success there is a high risk of recurrence, particularly due to the inability to create transmural lesions. Indeed, only the endocardium of the LV has been ablated, while a significant part of the arrhythmia substrate may be located on the other side of the myocardial thickness, on the epicardial side of the LV. First described in 1996, epicardial ablation, performed via a percutaneous subxyphoid approach, has since undergone considerable development. Electrophysiologists often use a double endo- and epicardial approach as first line therapy for the ablation of VTs complicating myocarditis or arrhythmogenic dysplasia of the right ventricle, where the substrate is most often epicardial. For VT in ischaemic heart disease, electrophysiologists perform endocardial ablation, and often perform epicardial ablation only after several endocardial failures. Several observational studies suggest that a combined endo- and epicardial approach as first line therapy is associated with a reduced risk of VT recurrence. Since recurrent VT in patients with ischaemic heart disease as a prognostic impact in terms of morbidity and mortality, it appears essential to optimise rhythm management by ablation, by offering a combined approach from the as first approach to reduce the risk of recurrences. The aim of our prospective, multicentre, controlled, randomized study is therefore to compare the rate of VT recurrence after ablation performed as first line therapy either by endocardial approach alone or by combined endo-epicardial approach.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05888662
Study type	Interventional
Source	Rennes University Hospital
Contact	Raphaël MARTINS, MD, PhD
Phone	299282517
Email	raphael.martins@chu-rennes.fr
Status	Recruiting
Phase	N/A
Start date	October 23, 2023
Completion date	October 23, 2028

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04066738` - Scar Location and Acute Haemodynamic Response to MultiPoint Pacing Study in Patients With Ischemic Cardiomyopathy	N/A
Recruiting	`NCT03536052` - Ablation at Virtual-hEart pRedicted Targets for VT	N/A
Enrolling by invitation	`NCT02930265` - Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy	N/A
Completed	`NCT01215253` - Ranolazine Implantable Cardioverter-Defibrillator Trial	Phase 3
Completed	`NCT04508608` - Scintigraphic Evaluation of Contractile and Coronary Reserve in Patients With Ischemic Cardiomyopathy
Completed	`NCT03857906` - Evaluation of Prophylactic Use of a Preoperative IABP in High-Risk Coronary Artery Bypass Graft Surgery
Completed	`NCT02501811` - Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure	Phase 2
Recruiting	`NCT02058771` - Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
Not yet recruiting	`NCT01946048` - Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy	Phase 1
Terminated	`NCT01759212` - Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure.	Phase 2/Phase 3
Not yet recruiting	`NCT01447069` - Use of Beta-agonists in Stable Severe Congestive Heart Failure	N/A
Recruiting	`NCT00972114` - CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Ischemic Cardiomyopathy	Phase 1/Phase 2
Completed	`NCT00896142` - Optima Coronary Artery Disease (CAD) (Optimal Mechanical Evaluation)	N/A
Recruiting	`NCT01076660` - Left Ventricular Structural Predictors of Sudden Cardiac Death
Completed	`NCT00305214` - MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients	N/A
Completed	`NCT00305240` - MASTER I - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients	N/A
Active, not recruiting	`NCT00962364` - Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease
Recruiting	`NCT05769036` - Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients	N/A
Completed	`NCT03862339` - The SoundScar Study The SOUNDSCAR Study
Recruiting	`NCT03830957` - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT) — EPIC-VT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms